ML-267

Phosphopantetheinylation is an essential post‐translational protein modification to primary and secondary metabolic pathways that ensures bacterial cell viability and virulence, and it is used in the production of many pharmaceuticals. Traditional methods have not provided a comprehensive understanding of these modifications. By using chemical proteomic probes for adenylation and thiolation domains in nonribosomal peptide synthetases (NRPSs), chemoproteomics has been applied to survey and validate the cellular activity of 4‐[3‐chloro‐5‐(trifluoromethyl)pyridin‐2‐yl]‐N‐(4‐methoxypyridin‐2‐yl)piperazine‐1‐carbothioamide (ML267), which is a potent and selective small‐molecule 4′‐phosphopantetheinyl transferase (PPTase) inhibitor that attenuates secondary metabolism and viability of bacterial cells. ML267 inhibited Sfp‐type PPTase and antagonized phosphopantetheinylation in cells, which resulted in a decrease in phosphopantetheinylated NRPSs and the attenuation of Sfp‐PPTase‐dependent metabolite production. These results indicate that this chemoproteomics platform should enable a precise interpretation of the cellular activities of Sfp‐type PPTase inhibitors.